サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1788213

核酸治療薬CDMOの世界市場

Nucleic Acid Therapeutics CDMO

出版日
ページ情報
英文 200 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.73円
核酸治療薬CDMOの世界市場
出版日: 2025年08月12日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 200 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

核酸治療薬CDMOの世界市場は2030年までに395億米ドルに到達

2024年に166億米ドルと推定される核酸治療薬CDMOの世界市場は、2024～2030年の分析期間においてCAGR 15.6%で成長し、2030年には395億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるRNAベースの治療薬は、CAGR 17.3%を記録し、分析期間終了時には283億米ドルに達すると予測されます。遺伝子治療分野の成長率は、分析期間中CAGR 11.8%と推定されます。

米国市場は44億米ドルと推定、中国はCAGR14.6％で成長予測

米国の核酸治療薬CDMO市場は、2024年に44億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに61億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは14.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ14.6%と13.3%と予測されています。欧州では、ドイツがCAGR 11.2%で成長すると予測されています。

世界の核酸治療薬CDMO市場- 主要動向と促進要因まとめ

なぜ核酸治療薬がバイオ医薬品サプライチェーンにおけるCDMOの役割を再構築しているのか？

アンチセンスオリゴヌクレオチド（ASOs）、低分子干渉RNA（siRNA）、メッセンジャーRNA（mRNA）、アプタマー、CRISPRベースの遺伝子エディターなどの核酸治療薬は、世界の医薬品業界においてパラダイムシフトを引き起こしています。希少な遺伝性疾患からがんや感染症に至るまで、以前は難治性であった疾患を治療する可能性が高まっており、研究と商業的関心の大きなうねりを生み出しています。こうした中、開発・製造受託機関（CDMO）は、デリバリー・パイプラインにおける不可欠なパートナーとして台頭してきました。従来の生物製剤や低分子化合物とは異なり、核酸治療薬にはオリゴヌクレオチド合成、酵素生産、脂質ナノ粒子製剤、無菌充填仕上げ工程など、高度に専門化された能力が要求されます。このような治療法の開発と規模拡大に伴う複雑さ、カスタマイズ、規制の厳しさにより、バイオ医薬品イノベーター、特に中小規模のバイオテクノロジー企業は、経験豊富なCDMOに製造業務を委託する傾向が強まっています。臨床パイプラインが成長し多様化するにつれ、CDMOはプロセスの最適化、分析法の開発、cGMP製造においてより戦略的な役割を担うようになり、前臨床段階から商業上市までの長期的な協力者となることが多いです。mRNAベースのCOVID-19ワクチンの成功は、核酸プラットフォームのスケーラビリティと商業的実行可能性も検証し、この分野における強固なインフラ、技術的専門知識、規制上の実績を持つCDMOへの需要をさらに加速させています。

技術力とインフラ投資はCDMOの差別化をどのように促進するか？

核酸治療薬市場の成熟に伴い、CDMOは進化するクライアントの要求に対応するため、サービス・ポートフォリオと技術力において大きな変革期を迎えています。高性能オリゴヌクレオチド合成プラットフォーム、自動精製システム、次世代分析ツールは、今やCDMOの競争力の中心となっています。これと並行して、業界ではRNAやDNA治療薬専用の製造スイート、モジュール式クリーンルーム施設、脂質ナノ粒子（LNP）カプセル化mRNAのような複雑な製剤に対応可能な高スループット充填仕上げラインへの大規模な投資が行われています。シングルユース・バイオリアクター・システム、密閉処理装置、マイクロ流体技術は、汚染リスクを最小限に抑え、収率を最適化するために採用されています。さらに、デジタルトランスフォーメーションは効率化の鍵となりつつあり、CDMOは電子バッチ記録、リアルタイムモニタリングシステム、データ駆動型プロセスコントロールを導入して品質保証を強化し、市場投入までの時間を短縮しています。差別化の重要な領域は、プロセス開発、分析特性評価からスケールアップ、規制文書化まで、統合されたエンドツーエンドのサービスを提供する能力にあります。早期段階での柔軟性と後期段階での拡張性を兼ね備えたCDMOは、開発スケジュールが前倒しされ、複雑な治療プロファイルを持つバイオテクノロジー企業の顧客からますます好まれるようになっています。戦略的買収、提携、地域情勢別拡大により競合情勢はさらに形成されつつあり、核酸治療の世界パイプラインをサポートできる専門インフラを構築するための競争が激化しています。

規制の複雑さと市場力学は、CDMOの機会状況をどのように形成しているか？

核酸治療薬が実験的プラットフォームから主流の治療法へと移行するにつれ、その開発と製造を取り巻く規制環境は急速に進化しています。FDA、EMA、PMDAなどの機関は、オリゴヌクレオチド合成、mRNA生産、LNP製剤についてより具体的なガイドラインを導入しており、CDMOにさらなるコンプライアンス負担を強いています。規制当局の先見性と強固な品質システムでこの複雑さを乗り切ることができるCDMOは、開発経路のリスク軽減を目指すバイオファーマの顧客からますます支持されるようになっています。さらに、早期承認、ファスト・トラック指定、希少疾病用医薬品の優遇措置の動向は、タイムラインの圧縮を生み出し、スポンサーは、迅速なスケールアップと技術移転で実績のあるCDMOへの依存度を高めざるを得ないです。同時に、コールドチェーン・ロジスティクス、GMP基準、各国の規制当局の期待における世界の格差は、CDMOに事業の多様化を促し、北米、欧州、アジア太平洋に地域ごとに準拠したハブを設立するよう迫っています。核酸CDMO分野の競合は、レガシーバイオロジクスメーカーや新興プレーヤーの参入によっても激化しており、能力増強、人材獲得、専門化が急増しています。さらに、希少疾患や個別化医療分野における価格圧力やコストに敏感な顧客は、CDMOにカスタマイズと製造効率のバランスをとるよう促しています。こうした市場力学は、CDMOと顧客の関係を再構築しているだけでなく、核酸治療薬のバリューチェーン全体にわたって、イノベーションに焦点を当てた品質主導のサービスモデルの出現を促しています。

核酸治療薬CDMO市場の成長の原動力は？

核酸治療薬CDMO市場の成長は、技術革新、進化するバイオ医薬品パイプライン、規制状況の変化、アウトソーシング動向の増加など、いくつかの要因によって牽引されています。第一に、バイオテクノロジー企業や製薬企業におけるmRNA、siRNA、ASO、遺伝子編集プログラムの急速な拡大が、専門的な開発・製造技術に対する持続的な需要を生み出しています。第二に、核酸ベースの医薬品、特に脂質ナノ粒子、コールドチェーンハンドリング、cGMPグレードの純度を必要とする医薬品の製造は技術的、物流的に複雑であるため、スポンサーはエンドツーエンドの能力を提供するCDMOとの提携を迫られています。第三に、mRNAワクチンの成功と核酸プラットフォームの広範な検証により、このセクターへの多額の投資が誘致され、既存のCDMOと新興CDMOの両方がインフラを拡大し、プロセス技術を革新することが可能になりました。第四に、開発期間の短縮と規制の迅速化が世界的に推し進められ、迅速な拡張性を確保しながら複雑なコンプライアンス要件に対応できるCDMOへの需要が高まっています。第五に、個別化医療、希少疾患治療、がん領域のパイプラインは核酸モダリティへの依存度を高めており、柔軟で機敏な製造パートナーの必要性をさらに高めています。加えて、バイオファーマ・セクター全体でアウトソーシングが増加しており、特に社内のキャパシティが限られている小規模・バーチャルなバイオテクノロジー企業によるアウトソーシングが、CDMOとの提携に対する継続的な需要に拍車をかけています。これらの要因が相まって、核酸治療薬に特化したCDMOの強固で高成長の世界市場が形成され、CDMOはバイオ医薬品イノベーションの次の波を起こす重要なイネーブラーとして位置付けられています。

セグメント

タイプ（RNAベース治療薬、遺伝子治療薬）;サービス（製造サービス、プロセス開発・最適化サービス、分析・品質管理サービス、その他サービス）;最終用途（バイオテクノロジー企業エンドユーザー、製薬企業エンドユーザー、政府・学術研究機関エンドユーザー）;用途（遺伝子疾患、希少疾患、感染症、その他用途）

調査対象企業の例

  • Agilent Technologies, Inc.
  • Ajinomoto Co., Inc.
  • Bachem Holding AG
  • BioCina Pty Ltd.
  • BIOSPRING GmbH
  • Catalent, Inc.
  • Corden Pharma International
  • Curia Global, Inc.
  • Danaher Corporation（Aldevron）
  • Eurogentec
  • FUJIFILM Diosynth Biotechnologies
  • Integrated DNA Technologies, Inc.
  • KNC Laboratories Co., Ltd.
  • LGC Limited
  • Lonza Group Ltd
  • Merck KGaA
  • Nitto Denko Avecia Inc.
  • Syngene International Limited
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec

AIインテグレイションズ

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32383

Global Nucleic Acid Therapeutics CDMO Market to Reach US$39.5 Billion by 2030

The global market for Nucleic Acid Therapeutics CDMO estimated at US$16.6 Billion in the year 2024, is expected to reach US$39.5 Billion by 2030, growing at a CAGR of 15.6% over the analysis period 2024-2030. RNA-based Therapies, one of the segments analyzed in the report, is expected to record a 17.3% CAGR and reach US$28.3 Billion by the end of the analysis period. Growth in the Gene Therapies segment is estimated at 11.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.4 Billion While China is Forecast to Grow at 14.6% CAGR

The Nucleic Acid Therapeutics CDMO market in the U.S. is estimated at US$4.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.1 Billion by the year 2030 trailing a CAGR of 14.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.6% and 13.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.2% CAGR.

Global Nucleic Acid Therapeutics CDMO Market - Key Trends & Drivers Summarized

Why Are Nucleic Acid Therapeutics Reshaping the Role of CDMOs in the Biopharmaceutical Supply Chain?

Nucleic acid therapeutics-comprising modalities like antisense oligonucleotides (ASOs), small interfering RNA (siRNA), messenger RNA (mRNA), aptamers, and CRISPR-based gene editors-are driving a paradigm shift in the global pharmaceutical landscape. Their growing potential to treat previously intractable diseases, from rare genetic disorders to cancer and infectious diseases, is generating a massive wave of research and commercial interest. In this context, contract development and manufacturing organizations (CDMOs) have emerged as essential partners in the delivery pipeline. Unlike traditional biologics or small molecules, nucleic acid therapeutics require highly specialized capabilities in oligonucleotide synthesis, enzymatic production, lipid nanoparticle formulation, and sterile fill-finish processes. The complexity, customization, and regulatory rigor involved in developing and scaling these therapies have prompted biopharma innovators-especially small and mid-sized biotech firms-to increasingly outsource their manufacturing operations to experienced CDMOs. As clinical pipelines grow and diversify, CDMOs are assuming more strategic roles in process optimization, analytical method development, and cGMP manufacturing, often becoming long-term collaborators from preclinical stages to commercial launch. The success of mRNA-based COVID-19 vaccines has also validated the scalability and commercial viability of nucleic acid platforms, further accelerating demand for CDMOs with robust infrastructure, technical expertise, and regulatory track records in this space.

How Are Technological Capabilities and Infrastructure Investments Driving CDMO Differentiation?

With the nucleic acid therapeutics market maturing, CDMOs are undergoing a significant transformation in their service portfolios and technological capabilities to keep pace with evolving client demands. High-performance oligonucleotide synthesis platforms, automated purification systems, and next-generation analytical tools are now central to a CDMO’s competitive edge. In parallel, the industry is seeing massive investments in dedicated manufacturing suites for RNA and DNA therapeutics, modular cleanroom facilities, and high-throughput fill-finish lines capable of handling complex formulations such as lipid nanoparticle (LNP) encapsulated mRNA. Single-use bioreactor systems, closed processing units, and microfluidic technologies are being adopted to minimize contamination risks and optimize yields. Moreover, digital transformation is becoming a key enabler of efficiency, with CDMOs deploying electronic batch records, real-time monitoring systems, and data-driven process control to enhance quality assurance and reduce time-to-market. A critical area of differentiation lies in the ability to provide integrated end-to-end services-from process development and analytical characterization to scale-up and regulatory documentation. CDMOs that offer early-phase flexibility combined with late-stage scalability are increasingly preferred by biotech clients with accelerated development timelines and complex therapeutic profiles. Strategic acquisitions, partnerships, and geographic expansions are further shaping the competitive landscape, as players race to build specialized infrastructure capable of supporting a global pipeline of nucleic acid therapies.

How Are Regulatory Complexity and Market Dynamics Shaping the CDMO Opportunity Landscape?

As nucleic acid therapeutics transition from experimental platforms to mainstream treatment modalities, the regulatory environment surrounding their development and manufacturing is rapidly evolving. Agencies such as the FDA, EMA, and PMDA are introducing more specific guidelines for oligonucleotide synthesis, mRNA production, and LNP formulation, which places additional compliance burdens on CDMOs. Those capable of navigating this complexity with regulatory foresight and robust quality systems are increasingly favored by biopharma clients aiming to de-risk their development paths. Moreover, the trend toward accelerated approvals, fast-track designations, and orphan drug incentives has created compressed timelines, compelling sponsors to rely more heavily on CDMOs with proven track records in rapid scale-up and tech transfer. Simultaneously, global disparities in cold-chain logistics, GMP standards, and local regulatory expectations are pushing CDMOs to diversify their operations and establish regionally compliant hubs in North America, Europe, and Asia-Pacific. The competitive intensity in the nucleic acid CDMO space is also heightened by the entry of legacy biologics manufacturers and emerging players, leading to a surge in capacity building, talent acquisition, and specialization. Additionally, pricing pressures and cost-sensitive clients in the rare disease and personalized medicine sectors are prompting CDMOs to balance customization with manufacturing efficiency. These market dynamics are not only reshaping CDMO-client relationships but are also fostering the emergence of innovation-focused, quality-driven service models across the nucleic acid therapeutics value chain.

What’s Driving the Growth of the Nucleic Acid Therapeutics CDMO Market?

The growth in the nucleic acid therapeutics CDMO market is driven by several factors spanning technological innovation, evolving biopharma pipelines, changing regulatory landscapes, and increasing outsourcing trends. First, the rapid expansion of mRNA, siRNA, ASO, and gene-editing programs across biotech and pharmaceutical companies is creating sustained demand for specialized development and manufacturing expertise. Second, the technical and logistical complexity of producing nucleic acid-based drugs-especially those requiring lipid nanoparticles, cold-chain handling, and cGMP-grade purity-is pushing sponsors to engage with CDMOs that offer end-to-end capabilities. Third, the success of mRNA vaccines and the broader validation of nucleic acid platforms have attracted significant investment into the sector, enabling both established and emerging CDMOs to expand infrastructure and innovate in process technology. Fourth, the global push toward faster development timelines and regulatory acceleration is driving demand for CDMOs that can navigate complex compliance requirements while ensuring rapid scalability. Fifth, personalized medicine, rare disease treatments, and oncology pipelines increasingly rely on nucleic acid modalities, further boosting the need for flexible, agile manufacturing partners. In addition, rising outsourcing across the biopharma sector-particularly by small and virtual biotech firms with limited in-house capacity-is fueling continuous demand for CDMO collaboration. Together, these factors are shaping a robust, high-growth global market for CDMOs specializing in nucleic acid therapeutics, positioning them as critical enablers of the next wave of biopharmaceutical innovation.

SCOPE OF STUDY:

The report analyzes the Nucleic Acid Therapeutics CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (RNA-based Therapies, Gene Therapies); Service (Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services, Other Services); End-Use (Biotech Companies End-Use, Pharmaceutical Companies End-Use, Government & Academic Research Institutes End-Use); Application (Genetic Disorders, Rare Diseases, Infectious Diseases, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • Agilent Technologies, Inc.
  • Ajinomoto Co., Inc.
  • Bachem Holding AG
  • BioCina Pty Ltd.
  • BIOSPRING GmbH
  • Catalent, Inc.
  • Corden Pharma International
  • Curia Global, Inc.
  • Danaher Corporation (Aldevron)
  • Eurogentec
  • FUJIFILM Diosynth Biotechnologies
  • Integrated DNA Technologies, Inc.
  • KNC Laboratories Co., Ltd.
  • LGC Limited
  • Lonza Group Ltd
  • Merck KGaA
  • Nitto Denko Avecia Inc.
  • Syngene International Limited
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Nucleic Acid Therapeutics CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Pipeline of RNA and DNA-Based Drugs Throws the Spotlight on CDMOs Specializing in Nucleic Acid Therapeutics
    • Increased Outsourcing by Emerging Biotechs Strengthens the Business Case for Full-Service Nucleic Acid CDMOs
    • Here's How mRNA Vaccine Success Has Expanded the Addressable Market Opportunity for Nucleic Acid Platforms
    • Growing Complexity of Nucleic Acid Manufacturing Spurs Demand for Specialized Facilities and Process Expertise
    • Advances in Lipid Nanoparticle (LNP) and Delivery Technologies Drive Adoption of CDMO Partnerships
    • Regulatory Acceleration for Orphan and Rare Disease Therapies Generates Demand for Agile Manufacturing Support
    • Personalized Medicine and Gene Editing Trends Propel Growth in Flexible, Small-Batch Nucleic Acid CDMO Services
    • End-to-End Service Integration and One-Stop Development Models Enhance CDMO Value Proposition for Biopharma Clients
    • Increased Focus on GMP Compliance and Quality Systems Strengthens CDMO Role in Commercial-Scale Manufacturing
    • Expansion of Global Clinical Trials and Decentralized R&D Drives Geographic Diversification of CDMO Operations
    • Digitalization and Process Automation in Nucleic Acid Manufacturing Boost Operational Efficiency and Transparency
    • Surging Demand for Plasmid DNA and Oligonucleotide APIs Fuels Infrastructure Investments Among CDMOs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nucleic Acid Therapeutics CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for RNA-based Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for RNA-based Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Gene Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Gene Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Rare Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Manufacturing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Manufacturing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Process Development & Optimization Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Process Development & Optimization Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Analytical & Quality Control Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Analytical & Quality Control Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Government & Academic Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Government & Academic Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nucleic Acid Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 30: USA Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • JAPAN
    • Nucleic Acid Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • CHINA
    • Nucleic Acid Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 54: China Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: China 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • EUROPE
    • Nucleic Acid Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • FRANCE
    • Nucleic Acid Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 72: France Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: France 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: France 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: France 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • GERMANY
    • Nucleic Acid Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Germany 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • ITALY
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Italy 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Italy 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • UNITED KINGDOM
    • Nucleic Acid Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 96: UK Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: UK 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: UK 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: UK 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Nucleic Acid Therapeutics CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Asia-Pacific 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 120: Rest of World Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Type - RNA-based Therapies and Gene Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of World 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Type - Percentage Breakdown of Value Sales for RNA-based Therapies and Gene Therapies for the Years 2025 & 2030
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Application - Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of World 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Application - Percentage Breakdown of Value Sales for Genetic Disorders, Rare Diseases, Infectious Diseases and Other Applications for the Years 2025 & 2030
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by Service - Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of World 6-Year Perspective for Nucleic Acid Therapeutics CDMO by Service - Percentage Breakdown of Value Sales for Manufacturing Services, Process Development & Optimization Services, Analytical & Quality Control Services and Other Services for the Years 2025 & 2030
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics CDMO by End-Use - Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of World 6-Year Perspective for Nucleic Acid Therapeutics CDMO by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Pharmaceutical Companies End-Use and Government & Academic Research Institutes End-Use for the Years 2025 & 2030

IV. COMPETITION